Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer
Molecular diagnostic tests help clinicians understand the underlying biological mechanisms of their patients’ breast cancer (BC) and facilitate clinical management. Several tissue-based mRNA tests are used routinely in clinical practice, particularly for assessing the BC recurrence risk, which can g...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/4/1087 |
| _version_ | 1797621928250310656 |
|---|---|
| author | Helena Čelešnik Uroš Potočnik |
| author_facet | Helena Čelešnik Uroš Potočnik |
| author_sort | Helena Čelešnik |
| collection | DOAJ |
| description | Molecular diagnostic tests help clinicians understand the underlying biological mechanisms of their patients’ breast cancer (BC) and facilitate clinical management. Several tissue-based mRNA tests are used routinely in clinical practice, particularly for assessing the BC recurrence risk, which can guide treatment decisions. However, blood-based mRNA assays have only recently started to emerge. This review explores the commercially available blood mRNA diagnostic assays for BC. These tests enable differentiation of BC from non-BC subjects (Syantra DX, BCtect), detection of small tumours <10 mm (early BC detection) (Syantra DX), detection of different cancers (including BC) from a single blood sample (multi-cancer blood test Aristotle), detection of BC in premenopausal and postmenopausal women and those with high breast density (Syantra DX), and improvement of diagnostic outcomes of DNA testing (variant interpretation) (+RNAinsight). The review also evaluates ongoing transcriptomic research on exciting possibilities for future assays, including blood transcriptome analyses aimed at differentiating lymph node positive and negative BC, distinguishing BC and benign breast disease, detecting ductal carcinoma in situ, and improving early detection further (expression changes can be detected in blood up to eight years before diagnosing BC using conventional approaches, while future metastatic and non-metastatic BC can be distinguished two years before BC diagnosis). |
| first_indexed | 2024-03-11T09:03:00Z |
| format | Article |
| id | doaj.art-683f089100624b21ab0978a7b58532a5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:03:00Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-683f089100624b21ab0978a7b58532a52023-11-16T19:35:54ZengMDPI AGCancers2072-66942023-02-01154108710.3390/cancers15041087Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast CancerHelena Čelešnik0Uroš Potočnik1Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, 2000 Maribor, SloveniaFaculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, 2000 Maribor, SloveniaMolecular diagnostic tests help clinicians understand the underlying biological mechanisms of their patients’ breast cancer (BC) and facilitate clinical management. Several tissue-based mRNA tests are used routinely in clinical practice, particularly for assessing the BC recurrence risk, which can guide treatment decisions. However, blood-based mRNA assays have only recently started to emerge. This review explores the commercially available blood mRNA diagnostic assays for BC. These tests enable differentiation of BC from non-BC subjects (Syantra DX, BCtect), detection of small tumours <10 mm (early BC detection) (Syantra DX), detection of different cancers (including BC) from a single blood sample (multi-cancer blood test Aristotle), detection of BC in premenopausal and postmenopausal women and those with high breast density (Syantra DX), and improvement of diagnostic outcomes of DNA testing (variant interpretation) (+RNAinsight). The review also evaluates ongoing transcriptomic research on exciting possibilities for future assays, including blood transcriptome analyses aimed at differentiating lymph node positive and negative BC, distinguishing BC and benign breast disease, detecting ductal carcinoma in situ, and improving early detection further (expression changes can be detected in blood up to eight years before diagnosing BC using conventional approaches, while future metastatic and non-metastatic BC can be distinguished two years before BC diagnosis).https://www.mdpi.com/2072-6694/15/4/1087breast cancerperipheral blooddiagnostic assaymRNA testtranscriptomeearly detection |
| spellingShingle | Helena Čelešnik Uroš Potočnik Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer Cancers breast cancer peripheral blood diagnostic assay mRNA test transcriptome early detection |
| title | Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer |
| title_full | Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer |
| title_fullStr | Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer |
| title_full_unstemmed | Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer |
| title_short | Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer |
| title_sort | blood based mrna tests as emerging diagnostic tools for personalised medicine in breast cancer |
| topic | breast cancer peripheral blood diagnostic assay mRNA test transcriptome early detection |
| url | https://www.mdpi.com/2072-6694/15/4/1087 |
| work_keys_str_mv | AT helenacelesnik bloodbasedmrnatestsasemergingdiagnostictoolsforpersonalisedmedicineinbreastcancer AT urospotocnik bloodbasedmrnatestsasemergingdiagnostictoolsforpersonalisedmedicineinbreastcancer |